Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

FoldRx Gets Funds From Fibrosis Group

August 20, 2007 | A version of this story appeared in Volume 85, Issue 34

Cystic Fibrosis Foundation Therapeutics, an affiliate of the Cystic Fibrosis Foundation, will invest $22 million in FoldRx Pharmaceuticals, a Cambridge, Mass.-based biotech firm that develops drugs to address diseases caused by misfolded proteins. The funds, to be distributed over five years, will drive the discovery and development of compounds to correct a misfolded protein associated with cystic fibrosis. FoldRx will employ its yeast-based, high-throughput screening system to determine the mechanism of the misfolding and then come up with small molecules that address that defect.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.